Pharmacyclics LLC and Janssen Biotech, Inc., together are committed to advancing scientific and medical understanding to  enhance patient care through the support of independent research in Oncology & Hematology.
Through our Clinical & Preclinical Investigator Sponsored Research program, we support investigators who have an interest in further exploring and gaining new and valuable information about the use of ibrutinib. Investigators and their sponsoring institution independently generate and submit a research proposal to our joint clinical or preclinical review committee, and assume all sponsor responsibilities if the study is approved.

The companies’ support of Investigator Sponsored Research may be provided in the form of study drug supply and/or funding. Our joint program is global, and currently considers research proposals relating to ibrutinib in Oncology & Hematology only.

To submit an application, please click below on your country of residence:

2018 Submission Period CLINICAL Window Opening PRE-CLINICAL Window Opening
Quarter 1 2nd Jan – 28th Feb  2nd Jan – 28th Feb
Quarter 2 Closed Closed
Quarter 3 2nd Jul – 31st Aug 2nd Jul – 31st Aug
Quarter 4 Closed Closed